Reactogenicity and antigenicity of rhesus rotavirus vaccine (MMU-18006) in newborn infants in Venezuela

Flores, Jorge; Daoud, Georgette; Daoud, Naimeh; Puig, M.; Martinez, M. Patron; Pérez‐Schael, Irene; Shaw, Robert D.; Greenberg, Harry B.; Midthun, Karen; Kapikian, Albert Z.

doi:10.1097/00006454-198811000-00006

Cited by 19 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is likely that our IgM assay would have been more efficient if the postvaccination serum had been drawn within 1 to 2 weeks instead of a month after vaccination. The insensitivity of the serum IgA, IgG, and IgM assays in a group of asymptomatically infected neonates is in contrast to our findings in 1to 5-month-old vaccinees and a previous study of neonates vaccinated with RRV (5,16). Larger numbers of neonates will have to be studied to determine the best parameters of vaccine take in this age group.…”

contrasting

confidence: 99%

Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates

et al. 1989

View full text Add to dashboard Cite

In a phase 1 study to evaluate human-rhesus rotavirus reassortant vaccines, 116 infants 1 to 5 months of age received one of the following five preparations: the serotype 1 reassortant, the serotype 2 reassortant, rhesus rotavirus (serotype 3), a bivalent preparation (serotypes 1 and 3), or a placebo. Seroresponses to the different vaccines were measured by plaque reduction neutralization assay (PRNA); rotavirus-specific immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays (ELISAs); and complement fixation (CF). The seroresponse rate, calculated by using a fourfold or greater antibody rise by any assay, was similar in the four vaccine groups (83 to 96%). When the data from all the vaccinees were pooled, IgA ELISA, IgG ELISA, and PRNA were comparable in detecting seroresponses (67, 62, and 70%, respectively) and more efficient than IgM ELISA (53%) and CF (44%). When the vaccinees were analyzed by age, the overall seroresponse rates were the same for infants 1 to 2 and 3 to 5 months old (90%). The IgA ELISA and PRNA were the most efficient for detecting antibody rises in both age groups. IgG ELISA was among the least efficient methods for detecting antibody rises in the younger age group but among the most efficient in the older age group (44 versus 78%). CF was among the least efficient methods in both age groups but was significantly better in the older age group than in the younger age group (54 versus 21%). Our findings show that ELISA, in particular rotavirus-specific IgA ELISA, is a sensitive indicator of vaccine takes in 1-to 5-month-old infants, the target population for vaccination. The ELISA should also be very useful in demonstrating natural rotavirus infections in field studies in which a stool specimen from a diarrheal episode is not always available. The ELISA has the advantages of being easier and quicker and requiring less serum than PRNA, but it does not give serotype-specific information about the immune response. * Corresponding author. tant human rotavirus serotypes are represented by the reassortants (serotypes 1, 2, and 4) and RRV (serotype 3). An integral part of early trials with these different rotavirus vaccine candidates is the evaluation of their immunogenicity. In this study, serologic responses in 1to 5-month-old

show abstract

contrasting

confidence: 99%

Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates

et al. 1989

View full text Add to dashboard Cite

show abstract

“…Neutralizing antibody has correlated with protection from infection or disease in humans and piglets in some studies (11,37,55,66), while protection in calves, humans, piglets, and mice has not correlated with serum or intestinal neutralizing antibody in other studies (6,14,68,70,72). The failure of monovalent animal or animal ϫ human reassortant live virus vaccines to induce significant protection in children is attributed to failure to induce heterotypic protective antibody to multiple serotypes of virus and has resulted in the belief that a successful rotavirus vaccine will need to induce neutralizing antibody to multiple serotypes of rotavirus (29,56).…”

Section: Discussionmentioning

confidence: 99%

Rotavirus virus-like particles administered mucosally induce protective immunity

O’Neal

Crawford

Estes

et al. 1997

J Virol

167

View full text Add to dashboard Cite

We have evaluated the immunogenicity and protective efficacy of rotavirus subunit vaccines administered by mucosal routes. Virus-like particles (VLPs) produced by self-assembly of individual rotavirus structural proteins coexpressed by baculovirus recombinants in insect cells were the subunit vaccine tested. We first compared the immunogenicities and protective efficacies of VLPs containing VP2 and VP6 (2/6-VLPs) and G3 2/6/7-VLPs mixed with cholera toxin and administered by oral and intranasal routes in the adult mouse model of rotavirus infection. VLPs administered orally induced serum antibody and intestinal immunoglobulin A (IgA) and IgG. The highest oral dose (100 microg) of VLPs induced protection from rotavirus challenge (> or = 50% reduction in virus shedding) in 50% of the mice. VLPs administered intranasally induced higher serum and intestinal antibody responses than VLPs administered orally. All mice receiving VLPs intranasally were protected from challenge; no virus was shed after challenge. Since there was no difference in immunogenicity or protective efficacy between 2/6- and 2/6/7-VLPs, protection was achieved without inclusion of the neutralization antigens VP7 and VP4. We also tested the immunogenicities and protective efficacies of 2/6-VLPs administered intranasally without the addition of cholera toxin. 2/6-VLPs administered intranasally without cholera toxin induced lower serum and intestinal antibody titers than 2/6-VLPs administered with cholera toxin. The highest dose (100 microg) of 2/6-VLPs administered intranasally without cholera toxin resulted in a mean reduction in shedding of 38%. When cholera toxin was added, higher levels of protection were achieved with 10-fold less immunogen. VLPs administered mucosally offer a promising, safe, nonreplicating vaccine for rotavirus.

show abstract

“…In addition, the genotype constellation of strain SA11 suggests that it is not closely related to major RV strains circulating in humans (e.g., Wa-like and DS-1-like genogroups) (20). Homologous RVs are more pathogenic and replicate more efficiently than heterologous RVs in homologous animals (21)(22)(23)(24)(25)(26)(27)(28). Although some RV strains isolated from humans harbor gene segments derived from animal RVs, most human RVs harbor gene segments similar to those of prototype strains Wa and DS-1 (3,(29)(30)(31).…”

mentioning

confidence: 99%

Reverse Genetics System for a Human Group A Rotavirus

Kawagishi

Nurdin

Onishi

et al. 2020

J Virol

View full text Add to dashboard Cite

Group A rotavirus (RV) is a major cause of acute gastroenteritis in infants and young children worldwide. Recently, we established an entirely plasmid-based reverse genetics system for simian RV strain SA11. Although that system was robust enough to generate reassortant RVs, including human RV gene segments, and enabled better understanding of the biological differences between animal and human RV strains, a complete reverse genetics system for human RV strains is desirable. Here, we established a plasmid-based reverse genetics system for G4P[8] human RV strain Odelia. This technology was used to generate a panel of monoreassortant viruses between human and simian RV strains for all of the 11 gene segments demonstrating full compatibility between human and simian RV strains. Furthermore, we generated recombinant viruses lacking the C-terminal region of the viral nonstructural protein NSP1 and used it to define the biological function of the interaction between NSP1 and its target protein β-transducin repeat-containing protein (β-TrCP) during viral replication. While the NSP1 truncation mutant lacking the C-terminal 13 amino acids displayed lower β-TrCP degradation activity, it replicated as efficiently as the wild-type virus. In contrast, the truncation mutant lacking the C-terminal 166 amino acids of NSP1 replicated poorly, suggesting that the C-terminal region of NSP1 plays critical roles in viral replication. The system reported here will allow generation of engineered recombinant virus harboring desired mutations, increase our understanding of the molecular biology of human RV, and facilitate development of novel therapeutics and vaccines. IMPORTANCE Reverse genetics, an approach used to generate viruses from cloned cDNA, has increased our understanding of virus biology. Worldwide research led to the development of an entirely plasmid-based reverse genetics system for the simian RV laboratory strain. Although the technique allows generation of gene-modified recombinant RVs, biological differences between animal and human RVs mean that reverse genetics systems for human RV strains are still needed. Here, we describe a reverse genetics system for the high-yield human RV strain Odelia, which replicates efficiently and is suitable for in vitro molecular studies. Monoreassortant viruses between simian and human RV strains and NSP1 mutant viruses generated by the rescue system enabled study of the biological functions of viral gene segments. This human RV reverse genetics system will facilitate study of RV biology and development of vaccines and vectors.

show abstract

Reactogenicity and antigenicity of rhesus rotavirus vaccine (MMU-18006) in newborn infants in Venezuela

Cited by 19 publications

References 0 publications

Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates

Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates

Rotavirus virus-like particles administered mucosally induce protective immunity

Reverse Genetics System for a Human Group A Rotavirus

Contact Info

Product

Resources

About